Uetrecht J P, Woosley R L
Clin Pharmacokinet. 1981 Mar-Apr;6(2):118-34. doi: 10.2165/00003088-198106020-00003.
There are several known therapeutic implications of acetylator phenotype; among them, the association of a higher incidence of procainamide- and hydralazine-induced lupus in slow acetylators. Presumably, this is because acetylation of the aromatic amine or hydrazine functional group leads to a non-toxic product. Several other drugs which have been implicated in drug-induced lupus also contain an aromatic amine or hydrazine group. The clinical and laboratory characteristics of drug-induced and idiopathic lupus are similar but the degree to which the pathophysiological mechanisms are related, if at all, is unknown. There is also evidence reported for an association between the slow acetylator phenotype and idiopathic lupus. If true, this relationship should provoke some new experimental approaches to investigation into the mechanism of idiopathic lupus.
乙酰化酶表型有几个已知的治疗意义；其中，慢乙酰化者中普鲁卡因胺和肼屈嗪诱发的狼疮发病率较高。据推测，这是因为芳香胺或肼官能团的乙酰化会产生无毒产物。其他几种与药物性狼疮有关的药物也含有芳香胺或肼基团。药物性狼疮和特发性狼疮的临床及实验室特征相似，但病理生理机制之间的关联程度（如果存在关联的话）尚不清楚。也有证据报道慢乙酰化酶表型与特发性狼疮之间存在关联。如果这是真的，这种关系应该会引发一些新的实验方法来研究特发性狼疮的发病机制。
